Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties

Peter Dreger*, Mauricette Michallet, Paul Bosman, Sascha Dietrich, Mohamad Sobh, Ariane Boumendil, Arnon Nagler, Christof Scheid, Jan Cornelissen, Dietger Niederwieser, Lutz Mueller, Elizabeth Vandenberghe, Ilaria Scortechini, Helene Schoemans, Niels S. Andersen, Juergen Finke, Domenico Russo, Per Ljungman, Jakob Passweg, Michel van GelderNadira Durakovic, Helene Labussiere-Wallet, Tobias Berg, Gerald Wulf, Wolfgang Bethge, Donald Bunjes, Stefan Stilgenbauer, Maria Elisa Canepari, Michel Schaap, Christopher P. Fox, Nicolaus Kroeger, Silvia Montoto, Johannes Schetelig

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

32 Citations (Web of Science)
Original languageEnglish
Pages (from-to)44-52
Number of pages9
JournalBone Marrow Transplantation
Volume54
Issue number1
DOIs
Publication statusPublished - Jan 2019

Keywords

  • TERM-FOLLOW-UP
  • HIGH-RISK CLL
  • EUROPEAN-SOCIETY
  • DISEASE-CONTROL
  • THERAPY
  • FAILURE
  • SURVIVAL
  • OUTCOMES
  • BLOOD
  • ERA

Cite this